Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.
about
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin.Novel antibacterial agents for the treatment of serious Gram-positive infections.Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacinGemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.Gemifloxacin: a new fluoroquinolone.Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Levofloxacin for the treatment of pyelonephritis.In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose.Two validated spectrofluorometric methods for determination of gemifloxacin mesylate in tablets and human plasma.Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.Staphylococcus aureus and Escherichia coli adhesion to human cells is reduced by sub-MICs of gemifloxacin.Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae.Chiral separation of gemifloxacin in sodium-containing media using chiral crown ether as a chiral selector by capillary and microchip electrophoresis.Chemiluminescence determination of gemifloxacin based on diperiodatoargentate (III)-sulphuric acid reaction in a micellar medium.
P2860
Q33559026-909C4EF6-DEB0-4466-B423-BDA3677686FCQ33559055-E923841E-6A46-4121-A5A5-E821B39976AFQ34098582-331540A8-BC4C-457B-AD10-708A083A5969Q34278283-A8674A4C-585A-4EE1-86BE-8F1FAFBD14F7Q34568425-3766B615-4CEF-419A-BCD1-C6981B79D525Q35073345-BF129654-AFE1-45B0-8B38-D6E7B51E8B29Q35374935-10B0976C-4F1D-4A7B-BB99-A97D21564AF7Q35798789-52C20340-EE15-44F8-9FD3-4A24FE8C0CAEQ37333151-7C334B07-EA43-4B83-B41B-86A92F2B9451Q37867123-FAAFEF02-094F-42D7-9D5C-BFCD09643FAEQ37995676-84449DDE-0008-4016-AD9B-16A0A7D43D0BQ38101380-BE1C0948-87B1-4DA8-B6C0-4C543BB1676CQ39477931-1FCA0EDC-426C-4BA5-97C6-989CB402A3BCQ40290562-95326269-F1ED-4FF5-AE27-FE72EEB47AF2Q41426318-7A25B97F-8440-4501-BE61-D8496856F722Q42588154-A5314198-B52E-4E4F-A64E-DE7E6B55AA13Q42844652-7ECDF552-6B9F-4BF6-BDCE-E60D4E47D7B6Q43916916-0942A550-0CA0-492E-A721-FE5A2F535F6AQ43918015-051919DD-E3A2-4A9D-9A4A-43B742BF72DFQ43938312-FD6345A7-4343-4FDE-92B1-04B584755A3AQ45997177-0070CA6E-3B8B-4AF0-AC1B-CF21EC04C0F1
P2860
Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacokinetics and tolerabil ...... l doses to healthy volunteers.
@ast
Pharmacokinetics and tolerabil ...... l doses to healthy volunteers.
@en
type
label
Pharmacokinetics and tolerabil ...... l doses to healthy volunteers.
@ast
Pharmacokinetics and tolerabil ...... l doses to healthy volunteers.
@en
prefLabel
Pharmacokinetics and tolerabil ...... l doses to healthy volunteers.
@ast
Pharmacokinetics and tolerabil ...... l doses to healthy volunteers.
@en
P2093
P2860
P1476
Pharmacokinetics and tolerabil ...... l doses to healthy volunteers.
@en
P2093
P2860
P304
P356
10.1128/AAC.44.6.1604-1608.2000
P407
P577
2000-06-01T00:00:00Z